Market's view on Faron Pharma
Published on April 2024
- A positive interview on Proactive was discussed which suggests favourable company prospects.
- Speculation about the company needing £30m funding to achieve more significant results later in the year and potentially out-licensing, with the share price possibly increasing multiple times from its current level.
- A stock watcher took a calculated risk based on today’s news, acknowledging a possible complete loss or significant gain within a 12-month period.
- Observations were made regarding the company’s need for additional funding as indicated by previous financial terms and covenants, with a stock watcher expressing relief over having sold shares before the last funding round due to anticipated cash flow problems.
- Positive updates from the company were highlighted, indicating promising developments in treatments with significant patient response rates in clinical studies.
- Prospects for the company’s manufacturing or distribution capabilities were queried, suggesting interest in its scalability.
- Discussions about the company preparing for a potential U.S. listing, with new hires aimed at making the company compliant with U.S. financial reporting standards.
- Speculation about the company preparing for an IPO in New York, with significant licensing deals discussed that could potentially involve billion-dollar milestones.